Navigating China’s 2025 Pharma Reforms: What Global Companies Must Know

China’s pharmaceutical landscape is undergoing one of the most significant regulatory transformations in its history. Led by the National Medical Products Administration, the 2025 reforms aim to align the country with global standards while fostering innovation and ensuring patient safety.

For global pharmaceutical companies, these reforms present a dual reality:

• Expanded market access opportunities 
• Higher regulatory expectations and compliance complexity 

With China emerging as a global hub for drug innovation, clinical trials, and advanced therapies, understanding these reforms is critical for long-term success.

What is China’s 2025 pharma reforms?
China’s 2025 pharma reforms introduce mandatory MAH systems, faster drug approvals, eCTD-based digital submissions, real-world evidence usage, stricter pharmacovigilance, and accelerated pathways for innovative therapies under the NMPA.

Key Pillars of China’s 2025 Pharma Reforms

1. Marketing Authorization Holder (MAH) System Expansion

China has fully implemented the Marketing Authorization Holder (MAH) system across all drug categories.

Key Requirements:

• Each drug must have a designated MAH responsible for its full lifecycle 
• MAH overseas: 
  • Manufacturing 
  • Quality control 
  • Distribution 
  • Pharmacovigilance 

Impact on Foreign Companies:

• Greater flexibility in outsourcing manufacturing 
• Ability to separate manufacturing from marketing authorization 
• Mandatory collaboration with local entities for compliance execution 

The MAH system shifts accountability to a single responsible entity, increasing transparency and regulatory control.

2. Accelerated Drug Approval Pathways

The National Medical Products Administration has introduced multiple pathways to speed up approvals.

Fast-Track Categories:

• Breakthrough therapies 
• Rare disease (orphan) drugs 
• Pediatric medicines 
• Urgently needed overseas drugs 

Key Mechanisms:

• Priority review designation 
• Conditional approvals 
• Rolling submissions (submit data in phases) 

These pathways significantly reduce time-to-market for innovative therapies.

3. Integration of Real-World Evidence (RWE)

China is increasingly accepting Real-World Evidence (RWE) as part of regulatory submissions.

Use Cases:

• Label expansion 
• Post-market studies 
• Supplemental approvals 

Regulatory Expectations:

• High-quality data sources 
• Ethical compliance 
• Transparent methodology 
• Statistical robustness 

Particularly impactful in:

• Oncology 
• Rare diseases 
• Chronic disease management 

4. Mandatory eCTD-Based Digital Submissions

China is transitioning to electronic Common Technical Document (eCTD) format as a standard submission model.

Key Features:

• Structured XML-based dossiers 
• Standardized submission modules 
• Improved lifecycle management 
• Faster review cycles 

Benefits:

• Reduced Administrative Burden 
• Improved data consistency 
• Alignment with global regulatory frameworks 

Digitalization is central to China’s regulatory modernization strategy.

5. Strengthened Pharmacovigilance (PV) Requirements

Drug safety regulations have become significantly stricter.

Key PV Requirements:

• Risk Management Plans (RMPs) 
• Real-time adverse event reporting 
• Periodic safety update reports 
• Signal detection and risk mitigation 

Enforcement:

• Increased inspections 
• Heavy penalties for non-compliance 
• Mandatory local PV systems 

Companies must establish robust, China-specific pharmacovigilance infrastructure.

6. Alignment with Global Regulatory Standards

China continues to harmonize its regulations with international frameworks.

Areas of Alignment:

• Good Manufacturing Practice (GMP) 
• Good Clinical Practice (GCP) 
• Good Laboratory Practice (GLP) 

Benefits:

• Acceptance of foreign clinical trial data 
• Reduced duplication of studies 
• Faster global development strategies 

This makes China a more integrated player in global drug development pipelines.

7. Cell & Gene Therapy (CGT) Regulatory Pathways

China is actively supporting advanced therapy medicinal products.

Key Developments:

• Dedicated review teams for CGTs 
• Accelerated approval pathways 
• Clearer regulatory guidance 

Focus Areas:

• CAR-T therapies 
• Gene editing technologies 
• Regenerative medicine 

China is positioning itself as a leader in next-generation therapeutics.

Comparison: Pre-2025 vs 2025 Reforms

Key Challenges for Global Pharma Companies

Strategic Opportunities in China

How Companies Should Prepare

To succeed under China’s 2025 reforms:

1. Strengthen Regulatory Intelligence

• Monitor updates from the National Medical Products Administration 
• Stay aligned with evolving guidelines 

2. Transition to eCTD Systems

• Implement compliant publishing tools 
• Ensure XML backbone readiness 

3. Build Robust RWE Capabilities

• Partner with hospitals and data providers 
• Ensure data integrity and traceability 

4. Establish Local Pharmacovigilance Systems

• Set up China-based safety teams 
• Implement real-time reporting frameworks 

5. Collaborate with Local Partners

• CROs for clinical trials 
• Local manufacturers 
• Regulatory consultants 

6. Optimize Market Entry Strategy

• Choose appropriate approval pathway 
• Leverage fast-tracks opportunities 

Quick Facts

• MAH system now mandatory for all drugs 
• eCTD required for regulatory submissions 
• RWE accepted approvals and lifecycle changes 
• Stronger pharmacovigilance enforcement 
• Fast-track approvals for innovative therapies 
• Increased global regulatory alignment 

Why This Matters

China’s 2025 reforms signal a shift toward a data-driven, innovation-focused regulatory ecosystem.

Under the leadership of the National Medical Products Administration, companies must demonstrate:

• Regulatory expertise 
• Data integrity 
• Safety accountability 
• Digital readiness 

Organizations that adapt early will gain:

• Faster approvals
• Competitive advantage
• Stronger market positioning

How Maven Supports China Pharma Compliance

Our Services

• China regulatory strategy & MAH guidance 
• eCTD publishing and submission support 
• RWE strategy and data validation 
• Pharmacovigilance system setup 
• Fast-track approval planning 
• Local partner coordination 

Why Choose Maven

• Deep expertise in China NMPA regulations 
• End-to-end compliance support 
• Proven success in global submissions 
• Faster, compliant market entry 

Prepare for China’s Pharma Transformation

Entering or expanding in China?

Partner with Maven for seamless compliance and faster approvals

• Avoid regulatory delays
• Ensure data and safety compliance
• Maximize market opportunities

Conclusion

China’s 2025 pharma reforms represent a major turning point in global drug regulation.

With a focus on:

• Digital transformation 
• Innovation acceleration 
• Global harmonization 
• Patient safety 

China is becoming a strategic priority market for pharmaceutical companies worldwide.

Early preparation, strong local partnerships, and investment in compliance systems will determine success in this rapidly evolving landscape.

FAQs

1. Who regulates pharmaceuticals in China?
The National Medical Products Administration.

2. What is the MAH system in China?
A system where one entity is responsible for the full lifecycle of a drug.

3. Is eCTD mandatory in China?
Yes, digital submissions using eCTD are becoming mandatory from 2025.

4. What is Real-World Evidence (RWE)?
Clinical data collected outside traditional trials used for regulatory decisions.

5. Are fast-track approvals available?
Yes, for breakthrough, rare disease, and pediatric drugs.

6. What are pharmacovigilance requirements?
Strict safety monitoring, reporting, and risk management systems.

7. How can foreign companies enter China?
By partnering locally, complying with MAH rules, and aligning with NMPA requirements.